IPO News | Yifang Biotech (688382.SH) submitted to the Hong Kong Stock Exchange

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on January 1, Yifang Biotechnology (Shanghai) Co., Ltd. (abbreviation: Yifang Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Securities is its sole sponsor. According to the prospectus, Yifang Biotech (688382.SH) is a development-driven biopharmaceutical company based in China with a global layout, focusing on a large number of major diseases such as tumors, autoimmune diseases, and metabolic diseases where there are a large number of unmet needs.

As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (befotinib (BPI-D0316) and gesorese (D 1553)), two clinical-stage core products (D-2570 and terisetrin (D-0502)), a clinical-stage candidate (dabinolate (D-0120)), and three pre-clinical candidate products (YF087, YF550 and YF057).